Close
GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us
Menu
GMP
FDA Academy
Downloadables
Bids and Awards
Careers
FAQs
Report
Contact Us
Facebook
Search
Home
About FDA
Transparency
Issuances
Advisories
Administrative Order
Executive Order
FDA Circular
FDA Memorandum
Memorandum Circular
Republic Act
Old Issuances
Old FDA Advisories
Services
eServices
ePortal
ePortal2
Doctrack
RRDportal
Menu
Home
About FDA
Transparency
Issuances
Advisories
Administrative Order
Executive Order
FDA Circular
FDA Memorandum
Memorandum Circular
Republic Act
Old Issuances
Old FDA Advisories
Services
eServices
ePortal
ePortal2
Doctrack
RRDportal
SARS-CoV-2 rS Protein Nanoparticle Vaccine [Covovax]
On 17 November 2021, the Food and Drug Administration (FDA)
issued authorization granting Farberco Life Sciences Inc. the emergency use approval of SARS-CoV-2 rS Protein Nanoparticle Vaccine [Covovax]
.
Product Information
English
For more information on reporting side effects, click
here
.
Shares